



Avaxia Biologics To Present AVX-470 Phase 1b Clinical Results at Upcoming Medical Conferences

LEXINGTON, Mass. – October 17, 2014 – [Avaxia Biologics, Inc.](#), a clinical-stage biopharmaceutical company developing gut-targeted antibody therapeutics for gastrointestinal diseases, announced today that next week it will present results from its successful Phase 1b clinical trial of AVX-470 in active ulcerative colitis at two medical conferences. AVX-470 is a gut-targeted anti-TNF antibody.

A presentation entitled “AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in-Human Trial” will be given by M. Scott Harris, M.D., Chief Medical Officer, on Tuesday, October 21 from 2:24 p.m. to 2:36 p.m. at United European Gastroenterology Week in Vienna, Austria.

A poster entitled “Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of AVX-470, an Oral, Bovine-Derived Anti-TNF Antibody, in Patients with Active Ulcerative Colitis (UC): Initial Human Experience,” poster number P1058, will be presented by Barbara S. Fox, Ph.D., Chief Executive Officer, and Deborah S. Hartman, Ph.D., Vice President of Research, on Monday, October 20 from 10:30 a.m. to 4:00 p.m. at the Annual Scientific Meeting of the American College of Gastroenterology in Philadelphia.

“We are thrilled to report positive results from our first-in-human Phase 1b clinical trial of AVX-470 in patients with active ulcerative colitis,” said Dr. Fox. “Not only did the trial meet its primary and secondary endpoints, but we observed consistent efficacy signals across multiple clinical and biomarker datasets that were exploratory endpoints in this trial. These results fully support moving the program into Phase 2 clinical development.”

About AVX-470

AVX-470 is the first gut-targeted anti-TNF antibody in clinical development. The lead indication is inflammatory bowel disease (IBD), a serious disease involving chronic inflammation of the intestinal tract. Currently marketed anti-TNF drugs are highly effective for the treatment of IBD. However, despite their success, these drugs have two significant drawbacks. One is that they must be infused or injected, whereas patients prefer oral medications. More importantly, they cause rare but serious side effects, such as risk of serious infection, because they dampen the immune system throughout the body, not just in the intestines where the disease occurs. As a result, these drugs are used mostly as a second- or third-line therapy, despite evidence that earlier use may improve patient outcomes. In contrast, AVX-470 is an orally administered antibody therapeutic that targets the gut, potentially improving safety and

efficacy over existing anti-TNF therapies. Avaxia believes that AVX-470 has the potential to become a first-line therapy that transforms the treatment of IBD.

About Avaxia Biologics

Avaxia leads the field of gut-targeted antibody therapeutics — orally administered, minimally absorbed antibody drugs that are designed to act locally in the gastrointestinal tract. Avaxia's clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease (IBD). This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is focused primarily on gastrointestinal diseases such as IBD, celiac disease and necrotizing enterocolitis, though our proprietary gut-targeted antibody platform can address any disease that has a biological target accessible via the gastrointestinal tract. www.avaxiabiologics.com

Contact

Avaxia Biologics:

Barbara S. Fox, Ph.D.

Chief Executive Officer

or

Michael D. Rivard

VP Corporate Development

781-861-0062

media@avaxiabiologics.com

Media:

MacDougall Biomedical Communications

Charles Liles, 781-235-3060

cliles@macbiocom.com